In a different paradigm, Cools et al. (2010) also revealed that dopaminergic medications decreased ‘distractor resistance’ in find more PD (see also Moustafa et al.,

2008). The results of the present study are consistent with the findings of previous reports that found no severe attentional dysfunction in early-stage PD (e.g. Rafal et al., 1984; Della Sala et al., 1986; Cossa et al., 1989; Lee et al., 1999; Kingstone et al., 2002; Koerts et al., 2009; Cristinzio et al., 2012), and indicate that dopamine agonists do not affect alerting, orienting and executive attention. Other researchers suggested that attentional dysfunction in PD is confined to internal cognitive control mechanisms (Brown & Marsden, 1988; Bennett et al., 1995). However, using the ANT, Zhou et al. (2012) demonstrated a selective deficit of the orienting network, although results also revealed that alerting and executive components might be compromised in a more advanced stage of the disease (see also Allcock et al., 2009; Vandenbossche et al., 2012). Results from animal models and human pharmacological studies suggest that dopamine is specifically related to the executive attentional network (Marrocco & Davidson, 1998). However, Robbins (2002) argued that in animals the systematic administration of dopaminergic agents predominantly affects response latency,

premature responses and omissions via the dorsal and ventral striatal systems. The administration of dopamine agonists in humans also modulates striatal and midbrain responses to reward (Riba et al., 2008; Abler et al., 2009). CYC202 order Our findings are consistent with the response speed hypothesis of systematic dopaminergic effects (Robbins, 2002) because the sole change after the administration of dopamine agonists was shorter mean reaction times. Dopamine agonists had no noticeable effects on the altering, orienting

and executive measures in contrast to attentional boost, which was significantly enhanced. This suggests that the attention indexes, as measured by the ANT, are dissociable from attentional boost. What is (-)-p-Bromotetramisole Oxalate the practical relevance of enhanced attentional boost? We found that changes in BIS-11 attentional impulsivity correlated with atypical attentional boost (enhanced memory for distractor-associated scenes). Housden et al. (2010) also reported impulsivity in medicated patients with PD. In the ABT, target stimuli are salient and rewarded, leading to the enhanced encoding of the background scene. Distractors are not rewarded, and therefore there is no enhanced encoding of the background scene. This latter omission of distractor-associated scenes is disinhibited in patients with PD receiving dopaminergic medications, which is in accordance with our previous results from a simple associative learning task (Nagy et al., 2012).